# A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

> **NCT04659785** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04659785
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659785, "A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04659785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*